ADJUVANT: Phase III Trial Evaluating Gefitinib vs Vinorelbine/Cisplatin in Completely Resected Stage II-IIIA (N1-N2) NSCLC With EGFR Activating Mutations

June 2-6, 2017; Chicago, Illinois
Adjuvant gefitinib for up to 2 years achieved superior DFS vs vinorelbine/cisplatin with no cases of interstitial lung disease.
Format: Microsoft PowerPoint (.ppt)
File Size: 618 KB
Released: June 7, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Download these expert-selected slides covering current recommendations on evaluating and treating patients for NTRK fusion-positive cancer, from Clinical Care Options (CCO).

George D. Demetri, MD Alexander Drilon, MD Theodore Laetsch, MD Released: June 16, 2021

EHR data analysis from ASCO 2021 showed that NGS testing and clinical trial participation were less likely among Black patients with NSCLC than White patients, as reported by Clinical Care Options (CCO)

Released: June 15, 2021

Download these expert-selected slides on slides on treating patients with NTRK-positive tumors with TRK inhibitors, from Clinical Care Options (CCO).

Alexander Drilon, MD Released: June 11, 2021

Download these expert-selected slides on slides on overcoming acquired resistance with TRK inhibitors, from Clinical Care Options (CCO).

Theodore Laetsch, MD Released: June 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue